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AdoptivetransferofspeciﬁccytotoxicTlymphocytes(CTL)andCytokineInducedKillerCells(CIK)followinggeneticengineering
of T-cell receptor zeta hold promising perspective in immunotherapy. In the present work we focused on the mechanisms of
anti-tumor action of eﬀectors transduced with an anti-CD19 chimaeric receptor in the context of B-lineage acute lymphoblastic
leukemia (B-ALL). Primary B-ALL blasts were eﬃciently killed by both z-CD19 CTL and z-CD19 CIK eﬀectors. The use of death
receptor mediated apoptosis of target cells was excluded since agonists molecules of Fas and TRAIL-receptors failed to induce
cell death. Perforin/granzyme pathway was found to be the mechanism of chimaeric eﬀectors mediated killing. Indeed, cytolytic
eﬀector molecules perforin as well as granzymes were highly expressed by CTL and CIK. CD19 speciﬁc stimulation of transduced
eﬀectors was associated with degranulation as attested by CD107 membrane expression and high IFN-γ and TNF-α release.
Moreoverinhibitorsoftheperforin-basedcytotoxicpathway,Ca2+-chelatingagentEGTAandConcanamycinA,almostcompletely
abrogated B-ALL blast killing. In conclusion we show that the cytolysis response of z-CD19 chimaeric eﬀectors is predominantly
mediated via perforin/granzyme pathway and is independent of death receptors signaling in primary B-ALL.
1.Introduction
Allogeneic hematopoietic stem cell transplantation consti-
tutes the main curative treatment of hematological malig-
nancies and disorders. The potency of the graft versus-
leukemia eﬀect varies widely depending on the type of
leukemia. For B-lineage acute lymphoblastic leukemia (B-
ALL), the graft versus-leukemia eﬀect is modest and con-
sequently disease relapse after transplantation is a major
contributor to treatment failure [1].
Adoptive cellular therapy such as donor lymphocyte
infusions achieves poor remission rates in patients with B-
ALL and is associated with a high incidence and severity of
graft-versus-hostdisease morbidity and mortality [2].Adop-
tive immunotherapy targeting chosen antigens selectively
expressed by leukaemic targets should separate graft-versus-
leukemia and graft-versus-host disease.
Ex vivo genetic engineering of T cells and Cytokine-
induced killer cells (CIK) using gene-transfer technology
should overcome these barriers and allow the production of
large numbers of leukaemia-speciﬁc eﬀector cells. Chimaeric
receptors are generated by joining the heavy and light chain
variable regions of a monoclonal antibody, expressed as a
single-chain Fv molecule, to the cytoplasmic T-cell receptor
zeta [3].2 Journal of Biomedicine and Biotechnology
Chimaeric immunoreceptors that use antibody-derived
single-chain variable domains bypass the requirement for
antigen processing and presentation by HLA molecules.
Modiﬁed eﬀectors exhibit speciﬁc lysis and cytokine secre-
tion upon exposure to tumor cells expressing the respective
target antigen [4] and shown protection in murine tumor
models [5].
CD19-speciﬁcchimaericCytotoxicTlymphocytes(CTL)
[6–8], z-CD19 natural killer cells (NK) [9], or z-CD19
CIK [10]e ﬀectors speciﬁcally recognize and kill CD19+
leukemia/lymphoma cells and primary B-ALL blasts. Never-
theless, the mechanisms of this lysis has never been studied.
Two main pathways of CTL-mediated cytotoxicity, that
is, granule exocytosis mediated by perforin/granzymes and
the death receptor-mediated Fas/Fas ligand (FasL) system,
have been identiﬁed [11]. More recently, tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) was found
to induce apoptosis in a variety of tumor cells and leukemia
[12]. Mechanisms that trigger apoptosis in target cells are
shared by CTL and NK cells.
Death receptors are members of the tumor-necrosis
factor (TNF) receptor superfamily and include a subfamily
that is characterized by an intracellular domain—the death
domain [13]. Decoy receptors are closely related to the
death receptors but lack a functional death domain. Death
receptors are activated by their natural ligands from the TNF
family. Ligands bind to their respective death receptors—
such as CD95, TRAIL-R1 (TNF-related apoptosis-inducing
ligand-R1 or Death Receptor 4), and TRAIL-R2 (DR5), then
the death domains attract the intracellular adaptor protein
FADD (Fas-associated death domain protein, also known as
MORT1), which, in turn, recruits the inactive proforms of
certain members of the caspase protease family. In contrast
totheDR4andDR5receptors,twoothercell-surfaceTRAIL-
receptors, DcR1 (Decoy Receptor 1 or TRAIL-R3) and DcR2
(TRAIL-R4), lack a functional death domain and cannot
transduce a proapoptotic signal. These “decoy receptors”
compete with DR4 and DR5 for TRAIL binding.
Apoptosis of target cells is also induced by the granule
exocytosis pathway. Upon binding of an eﬀector to a target
cell (by CTL-receptor and antigen on the target cell), the
content of the granules is released. These cytolytic granules
contain a number of proteins: perforin, a pore forming
protein, and granzymes A and B, serine proteases, which
are the main eﬀector molecules of the granule-mediated cell
death.
In the present work we show that tumor killing by
CTL and CIK cells transduced with zeta-CD19 receptor (z-
CD19)ispredominantlymediatedviatheperforin/granzyme
pathway and is independent of death receptors signaling in
primary B-ALL.
2.MaterialsandMethods
2.1. Cell Lines and Primary Lymphoma Cells. Cell lines were
obtained from the American Type Culture Collection (LGC
Standards, Molsheim, France). We used SupB15 (ALL-B)
and Raji (Burkitt’s lymphoma) CD19+ leukemia cell lines
and the CD19− Jurkat (ALL-T). They were maintained in
RPMI-1640 Glutamax (Invitrogen, Cergy Pontoise, France)
supplemented with 10% fetal calf serum, supplemented
with sodium pyruvate, gentamycin, and nonessential amino
acids.
Bone marrow cells and peripheral blood mononuclear
cells (PBMC) were collected from patients with B-ALL at
diagnosis who signed informed consent forms. Flow cytom-
etry analysis showed that, in all tested cases, blast inﬁltration
was >80% and 100% of the blasts which expressed the
CD19 antigen. All leukemia samples were cryopreserved and
subsequently thawed to be used in the experiments.
2.2. Plasmids and Retrovirus Production. The variable
domains of monoclonal antibody anti-CD19 fmc63 were
cloned as single-chain Fv (scFv) molecules in frame with
CH2-CH3-CD28tm-zeta in the SFG-retroviral construct by
Martin Pule, UCL, London, UK. The retroviral supernatant
was produced by FuGENE 6 (Roche Diagnostic S.p.A.,
Italy)—mediated cotransfection of 293-T cells with the
MoMLV gag-pol expression plasmid pEQ-PAM3(-E) (kindly
providedbyMartinPule),theRD114envexpressionplasmid
pRDF (kindly provided by Dr Yasu Takeuchi) and the SFG-
anti-CD19 CR vector. Supernatants containing retrovirus
were harvested 48 hours and 72 hours after transfection,
immediately frozen in dry ice, and stored at −80◦C until use.
293T cells were used to titrate virus concentration.
2.3.GenerationofEﬀectorsandRetroviralTransduction. EBV-
Speciﬁc CTLs and CIKs Cells were prepared from PBMC
obtained after centrifugation of fresh blood on a density
gradient using Ficoll-Hypaque (Eurobio, Les Ulis, France).
EBV-speciﬁc CTLs were produced as previously reported
[14] PBMCs (2 × 106)w e r ec o c u l t u r e dw i t h5× 104
gamma-irradiated (40Gy) autologous EBV lymphoblastoid
cell lines (LCLs) per well in a 24-well plate. Starting on
day 10, the responder cells were restimulated weekly with
irradiated LCLs at a responder-to-stimulator ratio of 4:1.
From day 14, 40IU/mL recombinant human interleukin-
2 (IL-2) (Proleukine, Chiron) was added twice a week.
Twenty-four hours to three days after the third stimulation,
the CTLs were transferred to a 24-well nontissue culture
plates (BD) precoated with 3.7μg/cm2 of the recombinant
ﬁbronectin fragment FN CH-296 (RetroNectin; TaKaRa
BioEurope, Gennevilliers, France). Transduction was per-
formed in culture medium supplemented with 40UI/mL IL-
2 and incubation for 48 hours at 37◦C and 5% CO2.T h e n ,
the viral supernatant was replaced by fresh medium and a
fourth stimulation was performed on day 24.
CIK cells were prepared as described previously [10]
Brieﬂy, PBMC were resuspended in medium completed with
1000U/mL recombinant human IFN-g (Sigma). The next
day, IL-2 and anti-CD3 (Orthoclone OKT3, Janssen-Cilag)
were added at 500IU/mL and at 50ng/mL, respectively. Cells
were cultured at the concentration of 3 ×106 cells/mL. Fresh
medium and 300IU/mL IL-2 were added weekly during
culture. The transduction process was analogous to the one
used for CTLs, except for IL-2, that was used at 600IU/mL.Journal of Biomedicine and Biotechnology 3
2.4. Flow Cytometric Analysis. The following aﬃnity-
puriﬁed mouse monoclonal ﬂuorescent conjugated anti-
bodies were used: anti-CD3, anti-CD45, antigranzyme A,
antigranzyme B and isotypic controls (BD Biosciences, le
Pont de Claix, France), anti-CD95 and anti-CD19 (Beckman
Coulter), and antiperforine (Diaclone). Unconjugated anti-
DR4 (HS101), DR5 (HS201), DcR1 (HS301), and DcR2
(HS402) were from Alexis (Lausen, Switzerland). Their
indirect staining was performed with a goat antimouse-PE
conjugated polyclonal F(ab )2 antibody (Beckman Coulter).
Granzymes and perforin intracellular staining was per-
form following permeabilization using 10 min. incuba-
tion with BD-Fixation/Permeabilization solution from BD-
Cytoﬁx/Cytoperm kit and incubation in PermWash buﬀer.
Detection of the genetically modiﬁed zeta-transfectant
was performed by the goat antihuman (GAH) IgG (H+L)
F(ab )2 fragment polyclonal antibodies (Beckman Coulter).
Down expression of CD45 was used to gate leukemia
blasts from nonleukaemic cells. B cell origin of leukaemic
gated cells was conﬁrmed by CD19 expression.
All labeling was performed in the dark at room temper-
ature. Analyses were performed using a FACSCanto II ﬂow
cytometer and Diva software (BD Biosciences).
2.5. Assay for Determining Sensitivity to Death Receptor-
Induced Apoptosis and Cytotoxicity. Target cells were labeled
with 50μCi chromium 51 for 1 hours at 37◦C and 5% CO2.
After 3 washes, labeled targets were plated in 96 wells plates
at 105 cells/well for apoptosis assay and 5 × 104 cells/well for
cytotoxic assay.
The sensitivity of cells to Fas- and TRAIL-mediated
apoptosis was investigated using 500ng/mL agonistic anti-
CD95 (IgM clone CH11; Alexis Biochemicals, San Diego,
CA) and 500ng/mL recombinant human soluble TRAIL
(KillerTRAIL; Alexis Biochemicals). Isotype IgM antibody
was used as control (500ng/mL, Beckman Coulter). Apop-
tosis was assayed following 4 and 18 hours of incubation at
37◦C and 5% CO2.
For cytotoxicity, eﬀector cells were added at various
eﬀector to target ratios. Final volumes were 200μLa n dw e r e
incubated for 4 hours at 37◦C and 5% CO2.
Subsequently, 35μL supernatant was removed from each
well and counted by the Top Count NXT (Perkin Elmer)
scintillation counter to determine experimental chromium
51 release. Spontaneous release was obtained from wells
receiving target cells and medium only, and total release was
obtained from wells receiving 1mg/mL Saponine (Sigma).
Percentage-speciﬁc apoptosis was calculated by the fol-
lowing formula: % apoptosis = 100 × (experimental release
−spontaneousrelease)/(totalrelease−spontaneousrelease).
Percentage-speciﬁc cytotoxicity was calculated by the
following formula: % cytotoxicity = 100 × (experimental
release − spontaneous release)/(total release − spontaneous
release).
2.6. Determination of Degranulation and Intracellular
Cytokine Staining. Chimaeric eﬀectors cells were stimulated
with SupB15 cell line (1:3 ratio) for 5h30. Anti-CD107a
and CD107b FITC antibodies (BD Biosciences) were added
in the medium at the beginning of the stimulation in the
presence of 0.7μL/mL GolgiStop (BD Biosciences) and
1μL/mL GolgiPlug (BD Biosciences). Cells were then labeled
with anti-CD3 and goat antihuman (GAH) IgG (H+L)
F(ab )2 antibodies. Then permeabilization of the cells was
performed using Cytoﬁx/Cytoperm kit (BD Biosciences).
IFN-γ and TNF-α intracellular staining was then performed
(BD Biosciences). Degranulation and cytokine production
was analyzed on CD3+ GAH− or CD3+ GAH+ T cells.
3. Results
3.1. Primary B ALL Blast Are Sensitive to z-CD19 CTL
and CIK-Mediated Cytolysis. CTL anti-EBV and CIK cells
transduced with zeta-CD19 receptor were controlled and
weresimilartoourpreviouspublications(seesupplementary
data). The zeta-CD19 receptor transduced eﬀectors were
used to assay primary B-ALL blasts lysis. A strong cytotoxic
activity was observed against all blasts assayed (Figure 1).
Thus, primary B-ALL blasts are sensitive to the killing by
anti-CD19-z CTL and anti-CD19-z CIK eﬀectors.
3.2. Poor Expression of Death Receptors and Ligand Sensibility
by B ALL Blasts. Since death receptor expression is a
prerequisite for susceptibility of target cells to receive the
apoptosis signal by death ligands expressed by eﬀector
cells, we investigated Blast cell surface expression by ﬂow
cytometry.
Expression of Fas was observed on 100% of Jurkat and
Raji cell lines and 60% of SupB15 (Figure 2(a)). In contrast,
all primary B-ALL blasts studied were almost negative for
Fas expression, with a frequency range of 1.5% to 7.5%
(Figure 2(b)).
TRAIL death inducing receptors DR4 and DR5 were
expressed by Jurkat and Raji with more than 49% and 65%
DR4+ cells, respectively and 100% DR5+ for both cell lines.
More than 60% of SupB15 expressed DR5 but no expression
of DR4 was observed. Primary B-ALL blasts expressed
heterogeneously DR4 and DR5. DR4 was expressed by 1.9%
to 14.5% of cells. DR5 was more strongly expressed by
leukaemic cells with a range of 3.3% to 40.8% of blasts
expressing this molecule. TRAIL decoy receptors DcR1
(TRAIL-R3) and DcR2 (TRAIL-R4) were not expressed by
Jurkat and SupB15, whereas 40% of Raji expressed DcR1.
Very interestingly, B-ALL blasts expressed DcR1 and DcR2
proportionallytodeathreceptors,theleukemiaexpressedthe
most DR4, and DR5 expressed the highest levels of decoy
receptors DcR1 and DcR2.
The absence of Fas expressed by blasts should result in
the resistance of blast cells to apoptosis triggered by FasL
expressed by eﬀectors. The proportional coexpression of
TRAIL-death receptors with decoy receptors could lead to
the absence of TRAIL-mediated apoptosis susceptibility by
B-ALL cells.
InordertoconﬁrmtheresistanceofB-ALLblasttocytol-
ysisinducedbydeathreceptors,weusedtheagonistantibody
anti-FascloneCH11andsolublerecombinanthumanTRAIL4 Journal of Biomedicine and Biotechnology
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Figure 1: Killing of SupB15 (positive control) and tumor cells. The experiment is representative of 5 independent experiments. Similar
results were produced with 3 donors of CTL and 2 donors of CIK.
(killerTRAIL) molecule on these cells (Figure 3). Apoptosis
of Jurkat positive control was induced after treatment by
anti-Fas and TRAIL-receptors apoptosis agonists. SupB15
was weakly sensitive to TRAIL, but not to Fas. Raji was
weaklysensitivetoFasbutnottoTRAIL.Asanticipatedfrom
phenotyping study, blasts were not sensitive to apoptosis
induced by Fas and very weakly or not to TRAIL-Receptors
Death induction.
We concluded that primary B-ALL blasts were not sensi-
tive to death receptor-induced killing or very weakly. These
results showed that eﬀector cells cannot use Fas/FasL and
TRAIL/TRAIL-R pathways to kill primary B-ALL leukaemic
targets.
3.3. z-CD19 CTL and CIK-Express Mediators of Cytotoxicity
and Express Membrane CD107 Granule Exocytosis-Associated
Molecule upon B Cell Stimulation. To go further into the
elucidation of eﬀector mechanisms, we then analyzed the
expression of perforin, granzyme-A, and granzyme-B by
the eﬀectors. We also compared the expression of these
cytotoxicity-associated molecules from the transduced pos-
itive populations versus not transduced CTL and CIK.
As shown in Figure 4(a), CTL and CIK expressed high
amounts of granzymes and perforin. Retroviral transduced
cells showed no alteration in the expression of perforin and
granzyme-A and -B (Figure 4(a)).
We concluded that chimaeric eﬀectors express molecules
implicated in the perforin/granzyme pathway and that the
transduction do not aﬀect the expression of these molecules.
We next directly examined the degranulation of anti-
CD19-z chimaeric eﬀectors by the CD107 degranulation
assay. This functional assay was coupled to the cytokine
release assay for IFN-γ and TNF-α. In order to analyze
only the speciﬁc response linked to the CD19 molecule
expressed by target cells, eﬀectors were stimulated by EBV
negative B cell line SupB15 but also by primary B-ALL blasts.
Nontransduced CTL and CIK were not stimulated by target
cells so that the response analyzed is only the transfectant-
speciﬁc stimulation.
The coculture of anti-EBV-z-CD19-CTL and z-CD19-
CIK eﬀectors with CD19+ targets was associated to a
high increase in CD107 surface expression as compared
to nontransduced eﬀectors (Figure 4(b)), showing granules
exocytosis.CD19-speciﬁcstimulationoftransducedeﬀectors
induced high secretion of both IFN-γ and TNF-α cytokines.
As expected nontransduced anti-EBV and CIK revealed only
a small background of cytokine production.
Altogether, results from perforin and granzymes expres-
sion with the CD107 degranulation assay highly support the
hypothesis of perforin/granzyme pathway used by eﬀectors.
Moreover, intracellular cytokine staining conﬁrmed trans-
duced CTL and CIK functionality associated with B-ALL
blasts target recognition and killing by eﬀectors.
3.4. Inhibition of Perforin/Granzyme Pathway Block z-
CD19 Chimaeric Eﬀectors Cytolysis. I no r d e rt oc o n ﬁ r m
the involvement of perforin/granzyme pathway, we used
speciﬁc inhibitors. The exocytosis of lytic granules isJournal of Biomedicine and Biotechnology 5
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Figure3:ApoptosisinducedonJurkat,SupB15,orRajicelllinesandB-ALLblastsbyagonistantibodyanti-Fas(cloneCH11)orrecombinant
human TRAIL (killerTRAIL) measured after 4 hours and 18 hours exposition. Isotype control (Ig) is indicated.
Ca2+-dependent. We used EGTA chelating agent of divalent
cations including Ca2+ to block granzymes exocytosis in the
presence of Mg2+ (used to allow adherence between eﬀectors
and targets). Inhibition of perforin/granzyme pathway were
also performed by Concanamycin A who degrades perforin
by increasing the pH of lytic granules and inhibits perforin-
based cytotoxic activity.
Anti-EBV-z-CD19-CTL and z-CD19-CIK eﬃciently
killed SupB15 and Raji (Figure 5) but were inhibited by the
presence of EGTA/MgCl2 or Concanamycin A, conﬁrming
the use of perforin/granzyme pathway by eﬀectors to kill
their targets. More interestingly, primary B-ALL blasts were
eﬃciently killed by transduced CTL and CIK eﬀectors but
the killing was abrogated in the presence of inhibitors of
degranulation or of perforin.
In conclusion, we have demonstrated that chimaeric
CTL and CIK eﬀectors killed B-ALL primary blasts via the
perforin/granzyme pathway.6 Journal of Biomedicine and Biotechnology
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Figure 4: z-CD19 chimaeric eﬀectors express mediators of cytotoxicity. (a) CTL and CIK eﬀectors were stained with antigranzyme A,
-granzyme B or -perforin antibodies. Transfectant expressions were detected by a goat antihuman IgG (GAH) labeling on CD3+ cells.
PercentagesandMFIareindicatedfromCD3+ cells.(b)CTLandCIKeﬀectorswerecoculturedinthepresenceofSupB15CD19+ stimulating
cellsorPrimaryB-ALLblasts(AmMax,RoNirandSpSeb).Degranulationofeﬀectorswasanalyzedbyanti-CD107aand-CD107bantibodies
gated on CD3+ cells. Similarly, IFN-γ and TNF-α speciﬁcally produced by responding eﬀectors were analyzed on CD3+ g a t e dc e l l s .S i m i l a r
results were produced with 2 donors of CTL and CIK.Journal of Biomedicine and Biotechnology 7
4. Discussion
Our data demonstrate that redirecting the speciﬁcity of
anti-EBV CTL and CIK via a CD19-speciﬁc chimaeric
immunoreceptor eﬃciently kills CD19+ leukaemic and lym-
phoma lines, as well as primary B-ALL cells. Targeting CD19
with genetically modiﬁed eﬀectors is a strategy that has
shown its potent killing eﬃcacy on primary B-ALL. The
eﬀectors used were T cells activated by the CD3-speciﬁc
antibody OKT3 [8], anti-virus speciﬁc CTL [6, 7], Natural
Killer cells [9], or CIK [10]. In the present study we used
EBV-speciﬁc CTL and CIK. Both eﬀectors eﬃciently lyse
tumors but the mechanisms by which chimaeric eﬀector
cells mediate killing of B-ALL blasts have not been studied
until now. Tumor cell sensibility and eﬀector-mediated lysis
mechanisms are important to evaluate in order to improve
the immunomonitoring of T cells and NK cells responses
following immunotherapy. The lysis of tumor targets is
mediated by cell death induced by distinct pathways [13, 14].
Tumorescapemayinpartbeassociatedtodefectivesignaling
allowing evasion to eﬀectors functionality. The mechanisms
of eﬀector-mediated lysis are therefore also important to
elucidate tumor escape strategies.
TheFas-FasLpathwayisaclassiceﬀectormechanismthat
CTL and NK cells use to lyse target cells [15]. More recently,
TRAIL was found to induce apoptosis in a variety of tumor
cellsandleukemia[12]uponbindingwithitsdeath-inducing
receptors, DR4 and DR5. At the cell surface, TRAIL binding
reﬂects a competition between death receptors (DR4 and
DR5) and so-called ‘decoy receptors’ (DcR1 and DcR2), that
are receptor homologs but cannot signal to FADD. So we
ﬁrst analyzed death receptors expressed by B-ALL blasts and
the apoptosis susceptibility of primary leukemia following
exposition to Fas and TRAIL-receptor agonists. Our data
indicate that primary B-ALL blasts poorly express Fas and
are not susceptible to Fas agonist-induced apoptosis. The
resistance of leukaemic cells towards Fas-mediated apoptosis
found in this study is in line with previous data describing
leukemia cell resistance to Fas ligation [16, 17]. Resistance
to Fas ligation can be associated to diﬀerent mechanisms
in leukemia such as over expression of proto oncogenes
or secretion of soluble Fas. In the present work, it seems
that lack of Fas expression on the membrane of B-ALL
blasts could explain the resistance to Fas pathway. Cell
surface expression analysis of TRAIL receptors showed that
primary B-ALL cells express the death-inducing receptors
DR4 and/or DR5 but also the decoy receptors DcR1 and/or
DcR2, potentially leading to a competition associated with
an absence of death signaling. In line with this hypothesis,
the use of human recombinant TRAIL on B-ALL cells failed
to induce blasts apoptosis. Data from primary precursor B-
cell ALL showing that TRAIL was only modestly eﬀective in
this tumor type was previously reported [18]. In contrast to
our ﬁndings, authors reported that the poor TRAIL activity
reﬂectedapoorexpressionofdeathreceptorsaswellasdecoy
receptors. This could be explained by the use of western blot
analysis instead of more sensitive ﬂow cytometry used in the
present study and availability of more speciﬁc (monoclonal)
antibodies for TRAIL-receptors expression analysis. Taken
together, expression analysis of death-inducing receptors
and agonists susceptibility demonstrates that primary B-ALL
blasts are almost not sensitive to Fas and TRAIL-mediated
apoptosis.Asaconsequence,speciﬁcchimaericeﬀectorslysis
of B-ALL blasts cannot use the FasL/Fas or TRAIL/TRAIL-
receptors pathways.
In order to investigate the perforin/granzyme pathway,
we ﬁrst analyzed the expression of the cytolytic eﬀector
molecules. Anti-EBV CTL and CIK eﬀector cells highly
e x p r e s s e dp e r f o r i na sw e l la sg r a n z y m eAa n dB .C o m -
parison of z-CD19 transduced eﬀectors to nontransduced
cells demonstrates that receptor modiﬁcations of both anti-
EBV CTL and CIK are not associated to an alteration
in the expression of cytolytic eﬀector molecules. High
expression of cytolytic eﬀector molecules argues in favor
of perforin/granzyme pathway all the more since some
experiments showed that granzymes and perforin expres-
sion correlates with cytolytic activity [19]. We then ana-
lyzed transduced eﬀectors functionality via the chimaeric
immunoreceptor z-CD19 following stimulation by SupB15
cell line but also by primary B-ALL blasts. Degranulation
is a necessary prerequisite to perforin-granzyme-mediated
killing. Upon eﬀectors activation, preformed cytotoxic gran-
ules move toward the outer membrane of the cell in a
polarized fashion toward the site of antigen presentation.
After reaching the plasma membrane, the membrane of
the granule and the plasma membrane merge, releasing
the contents of the granule into the extracellular space.
At this time, the CD107a and CD107b proteins from the
granule membrane are accessible at the cell surface for
speciﬁc antibody binding [20]. Our data indicate that both
genetically modiﬁed eﬀectors anti-EBV CTL and CIK highly
increased CD107 surface expression following CD19 speciﬁc
stimulation. The upregulation of surface CD107 attests the
degranulationofz-CD19chimaericeﬀectors.Thisfunctional
assay was completed by the analysis of IFN-γ and TNF-α
release. The production of these proinﬂammatory cytokines
is associated with the eﬀectors function and killing. CD19-
speciﬁc stimulation of anti-EBV CTL and CIK transduced
eﬀectors induced high secretion of both IFN-γ and TNF-
α cytokines showing high functionality of genetic modiﬁed
responding cells.
Then we show that cytotoxicity mediated by CD19-
speciﬁc human chimaeric anti-EBV CTL as well as CIK are
Ca2+-dependent, since addition of the Ca2+-chelating agent
EGTA to the assay medium resulted in complete abrogation
of cytotoxicity.
TheexocytosisoflyticgranulesisCa2+ dependentbutthe
up-regulation of FasL on the cell surface of eﬀectors requires
also extracellular Ca2+ [21]. Since in the present work we
have demonstrated that primary B-ALL are not susceptible
to the death induced by Fas pathway, we could conclude
that the cytotoxicity mediated by the z-CD19 eﬀectors is
perforin/granzyme-dependent. Moreover, the cytotoxicity
mediated by z-CD19 anti-EBV CTL and CIK was almost
completely inhibited by treatment with a potent inhibitor of
the perforin-based cytotoxic pathway, Concanamycin A.
In conclusion the ﬁndings reported in the present
work show that the cytolysis response of z-CD19 chimaeric8 Journal of Biomedicine and Biotechnology
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Figure 5: Speciﬁc Lysis of z-CD19 chimaeric eﬀectors is inhibited in the presence of perforin/granzyme inhibitors. Cytolytic activity of
eﬀectors was analyzed against SupB15 or Raji cell lines and B-ALL blasts (control) or in the presence of EGTA/MgCl2 or Concanamycin A.
eﬀectors is predominantly mediated via perforin/granzyme
pathway and is independent of death receptors signaling in
primary B-ALL. This has important implications since in
mouse models of allogeneic bone-marrow transplantation,
it was shown that donor T cells mediate graft versus host
disease primarily through the FasL eﬀector pathway, whereas
the graft-versus-leukaemia activity was mediated through
the perforin pathway [22]. The present work has important
implications on the monitoring of z-CD19 engineered
eﬀector cells therapy against B leukemia.
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